We are pleased to welcome Julie Simpson to our small but growing team at OCB as our new Sales and Business Development Manager.
Julie has extensive experience from 21 years commercial work in both pharmaceuticals and medical devices; in various roles from Sales to Training. Having worked with both blue chip and small companies, Julie brings a strong focus on patient outcomes coupled with operational know-how and will help to ensure OCB strives to give patients the best possible care.
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers is developing a range of predictive biomarkers that will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 21 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. ColoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer. Oxford Cancer Biomarkers is closely affiliated with The University of Oxford, where its founders lead research groups focused on translational cancer science.